WO2005116850A3 - Expression differentielle de marqueurs dans le cancer de l'ovaire - Google Patents

Expression differentielle de marqueurs dans le cancer de l'ovaire Download PDF

Info

Publication number
WO2005116850A3
WO2005116850A3 PCT/IB2005/002555 IB2005002555W WO2005116850A3 WO 2005116850 A3 WO2005116850 A3 WO 2005116850A3 IB 2005002555 W IB2005002555 W IB 2005002555W WO 2005116850 A3 WO2005116850 A3 WO 2005116850A3
Authority
WO
WIPO (PCT)
Prior art keywords
ovarian cancer
markers
polynucleotides
polypeptides
alone
Prior art date
Application number
PCT/IB2005/002555
Other languages
English (en)
Other versions
WO2005116850A2 (fr
WO2005116850A9 (fr
Inventor
Gad S. Cojocaru
Sarah Pollock
Zurit Levine
Alexander Diber
Guy Kol
Amir Toporik
Rotem Sorek
Dvir Dahary
Michal Ayalon-Soffer
Pinchas Akiva
Amit Novik
Yossi Cohen
Osnat Sella-Tavor
Shira Walach
Shirley Sameah-Greenwald
Ronen Shemesh
Maxim Shklar
Original Assignee
Compugen Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Compugen Ltd. filed Critical Compugen Ltd.
Priority to AU2005248530A priority Critical patent/AU2005248530A1/en
Priority to EP05780004A priority patent/EP1721257A2/fr
Priority to CA002554703A priority patent/CA2554703A1/fr
Priority claimed from US11/043,806 external-priority patent/US7368548B2/en
Publication of WO2005116850A2 publication Critical patent/WO2005116850A2/fr
Publication of WO2005116850A9 publication Critical patent/WO2005116850A9/fr
Publication of WO2005116850A3 publication Critical patent/WO2005116850A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention se rapporte à de nouveaux marqueurs du cancer de l'ovaire, qui sont à la fois sensibles et précis. Les marqueurs selon l'invention font l'objet d'une surexpression et/ou d'une expression différentielle en cas de cancer de l'ovaire, en particulier, par rapport à un tissu ovarien normal. La mesure desdits marqueurs, seuls ou combinés, dans des échantillons prélevés sur des patients, livre des informations que le diagnosticien peut mettre en corrélation avec un diagnostic probable de cancer de l'ovaire. Les marqueurs selon l'invention, seuls ou combinés, permettent d'atteindre un degré élevé de détection différentielle entre un cancer de l'ovaire et un état non cancéreux.
PCT/IB2005/002555 2004-01-27 2005-01-27 Expression differentielle de marqueurs dans le cancer de l'ovaire WO2005116850A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2005248530A AU2005248530A1 (en) 2004-01-27 2005-01-27 Differential expression of markers in ovarian cancer
EP05780004A EP1721257A2 (fr) 2004-01-27 2005-01-27 Expression differentielle de marqueurs dans le cancer de l'ovaire
CA002554703A CA2554703A1 (fr) 2004-01-27 2005-01-27 Expression differentielle de marqueurs dans le cancer de l'ovaire

Applications Claiming Priority (61)

Application Number Priority Date Filing Date Title
US- 1999-04-01
US53912804P 2004-01-27 2004-01-27
US53912904P 2004-01-27 2004-01-27
US60/539,128 2004-01-27
US60/628,231 2004-01-27
US60/539,129 2004-01-27
US62085304P 2004-10-22 2004-10-22
US62087404P 2004-10-22 2004-10-22
US62097504P 2004-10-22 2004-10-22
US62091604P 2004-10-22 2004-10-22
US62091804P 2004-10-22 2004-10-22
US62092404P 2004-10-22 2004-10-22
US62065604P 2004-10-22 2004-10-22
US62091704P 2004-10-22 2004-10-22
US62067704P 2004-10-22 2004-10-22
US62097404P 2004-10-22 2004-10-22
US62100404P 2004-10-22 2004-10-22
US60/620,918 2004-10-22
US60/620,917 2004-10-22
US60/620,924 2004-10-22
US60/620,975 2004-10-22
US60/620,916 2004-10-22
US60/620,874 2004-10-22
US60/620,974 2004-10-22
US60/620,677 2004-10-22
US60/620,853 2004-10-22
US60/620,656 2004-10-22
US60/621,004 2004-10-22
US62113104P 2004-10-25 2004-10-25
US60/621,131 2004-10-25
US62232004P 2004-10-27 2004-10-27
US62201704P 2004-10-27 2004-10-27
US60/622,320 2004-10-27
US60/622,017 2004-10-27
US62810104P 2004-11-17 2004-11-17
US62823104P 2004-11-17 2004-11-17
US62811204P 2004-11-17 2004-11-17
US62825104P 2004-11-17 2004-11-17
US62812304P 2004-11-17 2004-11-17
US62815604P 2004-11-17 2004-11-17
US62817804P 2004-11-17 2004-11-17
US62816704P 2004-11-17 2004-11-17
US62811104P 2004-11-17 2004-11-17
US62814504P 2004-11-17 2004-11-17
US62813404P 2004-11-17 2004-11-17
US62819004P 2004-11-17 2004-11-17
US60/628,190 2004-11-17
US60/628,167 2004-11-17
US60/628,112 2004-11-17
US60/628,178 2004-11-17
US60/628,134 2004-11-17
US60/628,156 2004-11-17
US60/628,111 2004-11-17
US60/628,251 2004-11-17
US60/628,123 2004-11-17
US60/628,101 2004-11-17
US60/628,145 2004-11-17
US63055904P 2004-11-26 2004-11-26
US60/630,559 2004-11-26
US11/043,806 US7368548B2 (en) 2004-01-27 2005-01-27 Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of prostate cancer
USNONE 2009-03-06

Publications (3)

Publication Number Publication Date
WO2005116850A2 WO2005116850A2 (fr) 2005-12-08
WO2005116850A9 WO2005116850A9 (fr) 2006-12-07
WO2005116850A3 true WO2005116850A3 (fr) 2010-06-17

Family

ID=37054357

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/002555 WO2005116850A2 (fr) 2004-01-27 2005-01-27 Expression differentielle de marqueurs dans le cancer de l'ovaire

Country Status (4)

Country Link
EP (1) EP1721257A2 (fr)
AU (1) AU2005248530A1 (fr)
CA (1) CA2554703A1 (fr)
WO (1) WO2005116850A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111518218A (zh) 2006-11-02 2020-08-11 阿塞勒隆制药公司 Alk1受体和配体拮抗剂及其用途
US10059756B2 (en) 2006-11-02 2018-08-28 Acceleron Pharma Inc. Compositions comprising ALK1-ECD protein
US8642031B2 (en) 2006-11-02 2014-02-04 Acceleron Pharma, Inc. Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
MX2010011998A (es) 2008-05-02 2011-04-11 Acceleron Pharma Inc Metodos y composiciones de pericitos para regular la angiogenesis y composicion de pericapilar.
CN108997498A (zh) 2008-12-09 2018-12-14 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649741B1 (en) * 1998-02-20 2003-11-18 The Board Of Trustees Of The University Of Arkansas TADG-15: an extracellular serine protease overexpressed in carcinomas

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649741B1 (en) * 1998-02-20 2003-11-18 The Board Of Trustees Of The University Of Arkansas TADG-15: an extracellular serine protease overexpressed in carcinomas

Also Published As

Publication number Publication date
AU2005248530A1 (en) 2005-12-08
CA2554703A1 (fr) 2005-12-08
EP1721257A2 (fr) 2006-11-15
WO2005116850A2 (fr) 2005-12-08
WO2005116850A9 (fr) 2006-12-07

Similar Documents

Publication Publication Date Title
WO2005072049A3 (fr) Expression differentielle de marqueurs en endometriose
WO2007056523A3 (fr) Procedes de diagnostic et de surveillance de la progression d'un cancer
BRPI0720371B8 (pt) métodos para diagnóstico ou monitoramento da progressão de câncer de próstata em um indivíduo e uso in vitro de pelo menos um homeodomínio contendo o fator de transcrição como um biomarcador para câncer de próstata
WO2007146668A3 (fr) Utilisation d'imp3 en tant que marqueur pronostique de cancer
WO2008008284A3 (fr) Biomarqueurs du cancer et méthodes d'utilisation
WO2006081473A8 (fr) Methodes de diagnostic et de pronostic de cancers epitheliaux
WO2009111470A3 (fr) Dosage de protéase
WO2007030928A3 (fr) Methodes permettant de diagnostiquer les etats pathologiques dus au cancer colorectal et au cancer de l'ovaire
MX355020B (es) Biomarcadores de cancer de pulmon y usos de los mismos.
WO2006093507A3 (fr) Methodes et systemes de prediction de l'evolution d'un cancer
WO2009012140A3 (fr) Sélection de médicament pour une thérapie contre le cancer des poumons utilisant des réseaux à base d'anticorps
WO2008048230A3 (fr) Procédés d'identification de cibles biologiques et instrumentation d'identification de cibles biologiques
WO2006121661A3 (fr) Domaine de resistance a base cellulosique pour capteur d'analyte
WO2008048508A3 (fr) Biomarqueurs pronostiques chez des patientes souffrant d'un cancer des ovaires
WO2006074360A3 (fr) Isoforme d'apolipoproteine a-ii utilisee en tant que biomarqueur pour le cancer de la prostate
WO2005116850A3 (fr) Expression differentielle de marqueurs dans le cancer de l'ovaire
WO2006133923A3 (fr) Diagnostic, pronostic, et prediction de la recurrence des cancers du sein
WO2006131783A3 (fr) Nouvelles sequences d'aminoacides et de nucleotides, et dosages et methodes d'utilisation afferentes dans le diagnostic du cancer du poumon
WO2006081248A3 (fr) Marqueurs du cancer et procedes de detection
WO2010028373A3 (fr) Procédés pour diagnostiquer le cancer et déterminer la survie globale et la survie sans maladie des patients atteints du cancer
WO2004057336A3 (fr) Utilisation de la nicotinamide n-methyltransferase comme marqueur du cancer colorectal
WO2002064015A8 (fr) Pin1 utilise comme marqueur pour le cancer de la prostate
WO2005124356A3 (fr) Utilisation d'une proteine cbp2 en tant que marqueur pour un cancer colorectal
WO2008104985A3 (fr) Procédés pour distinguer un carcinome squameux du poumon d'autres cancers du poumon à non-petites cellules
Tung et al. Significance of serum DKK1 as a diagnostic biomarker in hepatocellular carcinoma

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2554703

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005248530

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

ENP Entry into the national phase

Ref document number: 2005248530

Country of ref document: AU

Date of ref document: 20050127

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005248530

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005780004

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005780004

Country of ref document: EP